Skip to content

Study · Randomized controlled trial · n = 1,637 · 2006

3 results

Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.

Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Nov 2006Cited by 127 (Europe PMC)

PMID17002571 (opens in a new tab)DOI10.1359/jbmr.060802 (opens in a new tab)PepBankPUB-17002571
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In osteoporotic postmenopausal women, teriparatide reduced new vertebral fracture risk versus placebo across all endpoint BMD values.

    In plain wordsIn women with osteoporosis, teriparatide reduced new vertebral fracture risk compared with placebo across all final bone density values.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNew vertebral fracture risk across endpoint BMD values
    Study

    n = 1,637

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg/day · median 19 monthsAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, teriparatide significantly reduced the risk of new vertebral fracture for all endpoint BMD values.
    3 context sentences
    Summary · context
    The relationship between spine BMD and the risk of new vertebral fractures after teriparatide treatment was assessed using data from the Fracture Prevention Trial.
    Summary · context
    Postmenopausal women with osteoporosis (n = 1637) were randomized to placebo or teriparatide 20 or 40 microg/day for a median of 19 months.
    Summary · context
    Spine BMD was assessed at baseline and 18 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In osteoporotic postmenopausal women receiving teriparatide, mean spine BMD increased by 0.09 g/cm(2) across baseline BMD tertiles.

    In plain wordsIn women with osteoporosis receiving teriparatide, mean spinal bone density increased by 0.09 g/cm(2) across baseline bone density groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine BMD increase across baseline tertiles
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 microg/day · 18 monthsAs given in this study (human).

    Measurements

    Mean spine BMD increase
    0.09 g/cm(2)
    teriparatide, across baseline BMD tertiles

    Source sentences

    Summary
    The mean spine BMD increase in teriparatide-treated patients was 0.09 g/cm(2) across tertiles of baseline spine BMD.
    3 context sentences
    Summary · context
    The relationship between spine BMD and the risk of new vertebral fractures after teriparatide treatment was assessed using data from the Fracture Prevention Trial.
    Summary · context
    Postmenopausal women with osteoporosis (n = 1637) were randomized to placebo or teriparatide 20 or 40 microg/day for a median of 19 months.
    Summary · context
    Spine BMD was assessed at baseline and 18 months.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyMechanism

    In osteoporotic women, teriparatide-mediated spine BMD increases accounted for 30% to 41% of vertebral fracture risk reduction across baseline BMD tertiles.

    In plain wordsIn women with osteoporosis, teriparatide-related spinal bone density increases explained 30% to 41% of vertebral fracture risk reduction.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableFracture risk reduction explained by spine BMD increase
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Risk reduction explained by BMD
    30%
    low baseline spine BMD tertile
    Risk reduction explained by BMD
    41%
    high baseline spine BMD tertile

    Source sentences

    Summary
    Teriparatide-mediated increases in spine BMD accounted for 30% (in the low baseline spine BMD tertile) to 41% (in the high baseline spine BMD tertile) of the reduction in vertebral fracture risk.
    3 context sentences
    Summary · context
    The relationship between spine BMD and the risk of new vertebral fractures after teriparatide treatment was assessed using data from the Fracture Prevention Trial.
    Summary · context
    Postmenopausal women with osteoporosis (n = 1637) were randomized to placebo or teriparatide 20 or 40 microg/day for a median of 19 months.
    Summary · context
    Spine BMD was assessed at baseline and 18 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.